ESMO 2018 Congress

Oncology Meeting Resources

19 Oct - 23 Oct 2018, Munich, Germany

ESMO 2018

Securing access to optimal cancer care!

Presentations (slides) and webcasts are available to ESMO members according to the presenters' agreement to release them. Abstracts are open access. Congress attendees should access via the ESMO Conferences platform .
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
Meeting programmeFuture ESMO meetings

> ESMO Videos:  Highlights series   |  Expert Report series

Special Sessions and Tracks

More Resources





Format available

https://oncologypro.esmo.org/Meeting-Resour...-NET-6-Year-analysis-in-phase-III-NEOS-trial

BackgroundNEOS is a randomized phase III study that assessed the long-term prognosis of estrogen receptor positive (ER+) primary breast cancer (PBC) pts who received NET with/without adjuvant chemotherapy (CT).

Date: 19 Oct 2018
Presenter: Hiroji Iwata
Resources: Abstract, Presentation, Webcast
Topics: Anticancer Agents, Breast Cancer

https://oncologypro.esmo.org/Meeting-Resour...-in-the-prospective-multicenter-CANTO-cohort

BackgroundPrevious studies demonstrated that younger patients (pts) with breast cancer (BC) are more likely to be non-adherent to adjuvant ET, leading to impaired prognosis.

Date: 19 Oct 2018
Presenter: Barbara Pistilli
Resources: Abstract, Presentation, Webcast
Topics: Anticancer Agents, Breast Cancer

https://oncologypro.esmo.org/Meeting-Resour...early-stage-Invited-Discussant-184O-and-185O

Date: 19 Oct 2018
Presenter: Helena Earl
Resources: Presentation
Topic: Breast Cancer

https://oncologypro.esmo.org/Meeting-Resour...trastuzumab-in-the-randomized-ShortHER-trial

BackgroundTILs are an established prognostic factor for triple negative breast cancer. We investigated the prognostic role of TILs for HER2+ early breast cancer patients enrolled in the prospective ShortHER trial.

Date: 19 Oct 2018
Presenter: Maria Vittoria Dieci
Resources: Abstract, Presentation, Webcast
Topics: Anticancer Agents, Breast Cancer

https://oncologypro.esmo.org/Meeting-Resour...year-follow-up-of-a-randomized-phase-3-study

BackgroundAdjuvant HDCT for high-risk BC is not beneficial overall compared to conventional chemotherapy at the cost of considerable toxicity. HDCT benefit, however, may be present in very high-risk patients (i.

Date: 19 Oct 2018
Presenter: Tessa Steenbruggen
Resources: Abstract, Presentation, Webcast
Topics: Anticancer Agents, Breast Cancer

https://oncologypro.esmo.org/Meeting-Resour...Invited-Discussant-one-LBA-TBC-186O-and-187O

Date: 19 Oct 2018
Presenter: Javier Cortes Castan
Resources: Presentation, Webcast
Topic: Breast Cancer

https://oncologypro.esmo.org/Meeting-Resour...eal-metastasis-a-randomised-open-label-trial

BackgroundThe role of intra-cerebrospinal fluid (CSF) therapy for the treatment of leptomeningeal metastasis (LM) remains controversial.MethodsWe conducted a multicenter randomized open-label study to...

Date: 19 Oct 2018
Presenter: Emilie Le Rhun
Resources: Abstract, Presentation
Topics: Anticancer Agents, Breast Cancer, Central Nervous System Malignancies

https://oncologypro.esmo.org/Meeting-Resour...ancer-patients-EORTC-QLQ-BC23-EORTC-QLQ-BR45

BackgroundThe EORTC QLQ-BR23 was one of the first disease specific questionnaire developed in 1996 to assess quality of life (QoL) in patients with breast cancer (BC).

Date: 20 Oct 2018
Presenter: Vesna Bjelic-Radisic
Resources: Abstract, Presentation, Webcast
Topics: Supportive Measures, Breast Cancer

https://oncologypro.esmo.org/Meeting-Resour...ociclib-fulvestrant-results-from-MONALEESA-3

BackgroundIn the MONALEESA-3 trial (NCT02422615), ribociclib + fulvestrant significantly improved progression-free survival (PFS) vs placebo + fulvestrant in patients with hormone receptor-positive,...

Date: 20 Oct 2018
Presenter: Peter A. Fasching
Resources: Abstract, Presentation, Webcast
Topics: Anticancer Agents, Supportive Measures, Breast Cancer

https://oncologypro.esmo.org/Meeting-Resour...C-MONALEESA-7-patient-reported-outcomes-PROs

BackgroundIn the Phase III MONALEESA-7 trial (NCT02278120), RIB + TAM/NSAI + goserelin (GOS) significantly improved progression-free survival vs placebo (PBO) + TAM/NSAI + GOS in premenopausal pts with...

Date: 20 Oct 2018
Presenter: Nadia Harbeck
Resources: Abstract, Presentation, Webcast
Topics: Anticancer Agents, Breast Cancer